

# A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditions

Published: 01-04-2008

Last updated: 07-05-2024

nvt

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Other condition
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON32022

### Source

ToetsingOnline

### Brief title

ASP2905 SAD/food effect study

### Condition

- Other condition

**Synonym**

Alzheimer's Disease and schizophreny

**Health condition**

ziekte van Alzheimer, schizofrenie

**Research involving**

Human

**Sponsors and support**

**Primary sponsor:** Astellas Pharma

**Source(s) of monetary or material Support:** sponsor

**Intervention**

**Keyword:** Alzheimer, ASP2905, Food effect, SAD

**Outcome measures****Primary outcome**

nvt

**Secondary outcome**

nvt

**Study description****Background summary**

nvt

**Study objective**

nvt

**Study design**

nvt

**Intervention**

2 - A double-blind, randomized, placebo-controlled study to assess the safety, toler ... 4-05-2025

nvt

## Study burden and risks

nvt

## Contacts

### Public

Astellas Pharma

Elisabethhof 19  
2350 AC Leiderdorp  
Nederland

### Scientific

Astellas Pharma

Elisabethhof 19  
2350 AC Leiderdorp  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

- Healthy young male subject, aged 18-50 years inclusive.

## Exclusion criteria

current clinically significant diseases or conditions or any clinical significant diseases or conditions in medical history.

## Study design

### Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	04-05-2008
Enrollment:	68
Type:	Actual

### Medical products/devices used

Product type:	Medicine
Brand name:	nvt
Generic name:	placebo

## Ethics review

Approved WMO	
Date:	01-04-2008
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

(Assen)

Approved WMO

Date: 08-04-2008

Application type: First submission

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO

Date: 28-08-2008

Application type: Amendment

Review commission: BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	EUCTR2007-006108-39-NL
CCMO	NL22674.056.08